Home  /  Resource Library  /  Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

Results of a phase I study involving Brentuximab Vedotin in combination with cyclophosphamide, doxorubicin, and prednisone for front line treatment of CD30 positive T-cell lymphomas.